MetaSight has developed next generation Metabolomics/Lipidomics technologies for allowing unbiased, high throughput analyses of full metabolic profiles. The company’s methods generate highly sensitive and affordable early diagnostic biomarkers for various pathologies including cancer, metabolic diseases, autoimmunity, and neurodegenerative disorders.

Investing partner / fund: